omniture
logo
Search
CALIWAY BIOPHARMACEUTICALS
Media Room

Latest News

rss

Caliway Closes Oversubscribed Capital Raise and Secures Over $100M to Advance CBL-514 Pivotal Phase 3 Study in Subcutaneous Fat Reduction

TAIPEI, Dec. 16, 2023 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that it has cl...

2023-12-16 15:47 2553

Caliway's CBL-514 Achieved Better Efficacy than Liposuction, Reducing over 300mL of Subcutaneous Fat on Average in CBL-0202 Study

- CBL-0202 Phase 2 study results met all the primary and secondary endpoints. - 69.9% and 60.9% of p...

2023-10-02 21:00 1768

Caliway Announces the Completion of Subject Recruitment in the CBL-0201EFP Phase 2-stage 2 Study Evaluating the CBL-514 in Cellulite Treatment

TAIPEI, Sept. 18, 2023 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway), a biopharmaceutical co...

2023-09-19 11:16 1597

Caliway Announces CBL-514 Phase 2 Study Topline Results for Dercum's Disease, Showing 64.5% of Lipomas with Complete Clearance or Dimensions Reduction of Over 50% and Reduced Pain by 4.7

-       CBL-0201DD Phase 2 study met the primary and all secondary endpoints. -       64.5% of pain...

2023-09-13 13:42 1772

Caliway Announces Positive Data from CBL-0201EFP Phase 2-Stage 1 Study of CBL-514 in Treating Moderate to Severe Cellulite

* CBL-514 is the only non-invasive product that can improve 1-level of cellulite severity two wee...

2023-06-28 18:30 2243

Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2b Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction

- Caliway has initiated the subject recruitment in CBL-0204 Phase 2b study. - The study is expected...

2023-05-31 20:15 3907
Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2b Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction
12